New Results Reveal Unprecedented Inhibition Rates and First Evidence of SIL204's Efficacy Against Previously Untested KRAS Q61H Mutation in Human Cancer Cells, Significantly Expanding its Pan-KRAS Potential; Company on track for the initiation of a Phase 2/3 clinical trial in Q2 2026Grand Cayman, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancer ...

Biogen (BIIB) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Company ParticipantsTim Power - Head of IRChristopher Viehbacher - President, CEO & DirectorPriya Singhal - EVP & Head - DevelopmentAlisha Alaimo - President & Head - North AmericaRobin Kramer - EVP & CFOPhilip Nadeau - MD, Health Care – BiotechnologyMichael Yee - Managing DirectorUmer Raffat - Senior Managing DirectorBrian Abrahams - MD & Co-Head of Biotechnology ResearchSalveen Richter - Biotechnology Equity ResearchConference Call Participants ...

Amicus Therapeutics (FOLD) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Second Quarter twenty twenty five Financial Results Conference Call and Webcast. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr.An ...

Alnylam Pharmaceuticals (ALNY) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Alnylam Q2 twenty twenty five Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 07/31/2025. I would now like to turn the conference over to the company.Please go ahead.Speaker1Good morning. I'm Christina Kinch, Chief Corporate Communicati ...

argenx SE (ARGX) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning. My name is Rob, and I will be your conference operator today. I would like to welcome everyone to the call. At this time, all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.Thank you. I'd now like to introduce Bess Del Jocco, Vice President, Corporate Communications and Investor Relations. You may begin your call.Speaker1Thank you. A ...

Biogen (BIIB) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning. My name is Cynthia, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter twenty twenty five Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer question remarks, Today's conference is being recorded. AndThank you. I would now like to turn the ...

文章核心观点 - 公司宣布公开发行普通股定价，预计获得约575万美元毛收入，用于营运资金和一般公司用途 [1][2] 发行情况 - 公司为全球生物技术公司，宣布以每股0.95美元价格公开发行605.2万股普通股，预计毛收入约575万美元，发行预计8月1日完成 [1] - Craig - Hallum Capital Group LLC担任此次发行的独家主承销商 [2] 资金用途 - 公司打算将发行所得净收入用于营运资金和一般公司用途，如产品开发、销售和营销 [2] 注册声明 - 证券发行依据2023年8月9日向美国证券交易委员会提交并于8月25日生效的S - 3表格有效暂搁注册声明 [3] 公司介绍 - 公司利用专有微生物平台生产重组蛋白，产品销售或授权给生命科学、食品营养和生物工业市场的合作伙伴，C1和Dapibus™表达系统支持灵活且经济高效的制造 [5] 联系方式 - 公司首席财务官为Ping W. Rawson，联系电话(561) 743 - 8333，邮箱ir@dyadic.com [8]

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=158785&from=4 CLASS PERIOD: March 7, 2024 to March 3, 202 ...

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR).Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/capricor-loss-submission-form/?id=158796&from=4CLASS PERIOD: October 9, 2024 ...

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry Paves way for advances in precision kidney disease care, novel therapies, and diagnosticsBAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clin ...